Becton Dickinson Past Earnings Performance
Past criteria checks 1/6
Becton Dickinson has been growing earnings at an average annual rate of 13.5%, while the Medical Equipment industry saw earnings growing at 11.3% annually. Revenues have been growing at an average rate of 3% per year. Becton Dickinson's return on equity is 5.1%, and it has net margins of 6.5%.
Key information
13.5%
Earnings growth rate
12.2%
EPS growth rate
| Medical Equipment Industry Growth | 8.9% |
| Revenue growth rate | 3.0% |
| Return on equity | 5.1% |
| Net Margin | 6.5% |
| Next Earnings Update | 02 May 2024 |
Recent past performance updates
Recent updates
Investors Still Waiting For A Pull Back In Becton, Dickinson and Company (NYSE:BDX)
Mar 23
Estimating The Fair Value Of Becton, Dickinson and Company (NYSE:BDX)
Feb 29Becton Dickinson's (NYSE:BDX) Conservative Accounting Might Explain Soft Earnings
Feb 08Becton, Dickinson and Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Feb 03These 4 Measures Indicate That Becton Dickinson (NYSE:BDX) Is Using Debt Reasonably Well
Feb 01Becton, Dickinson: 4 Reasons To Buy This Growth At A Reasonable Price Play
Jan 22Becton Dickinson's (NYSE:BDX) Shareholders Will Receive A Bigger Dividend Than Last Year
Nov 30Becton, Dickinson And Company: Strong Q4 But Clouded By 75bps Growth Headwind From China In FY24
Nov 13Becton Dickinson's (NYSE:BDX) Upcoming Dividend Will Be Larger Than Last Year's
Nov 12Becton, Dickinson and Company's (NYSE:BDX) Intrinsic Value Is Potentially 26% Above Its Share Price
Nov 06With EPS Growth And More, Becton Dickinson (NYSE:BDX) Makes An Interesting Case
Oct 05Becton, Dickinson Stock Is A Hold, Here's Why
Oct 04Becton, Dickinson: Ahead Of Schedule, Undervalued, And With Some Positive Drivers
Aug 30We Think Becton Dickinson (NYSE:BDX) Can Stay On Top Of Its Debt
Aug 13Estimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)
Jul 28Here's Why We Think Becton Dickinson (NYSE:BDX) Is Well Worth Watching
Jun 22Becton, Dickinson and Company: Still Not Very Healthy
Jun 20Becton, Dickinson: Business Should Beat H2 2023 Expectations
Jun 08These 4 Measures Indicate That Becton Dickinson (NYSE:BDX) Is Using Debt Reasonably Well
Apr 22Is Now The Time To Put Becton Dickinson (NYSE:BDX) On Your Watchlist?
Mar 20Estimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)
Mar 05Becton, Dickinson HPV test Onclarity gets FDA nod for expanded use
Feb 21Becton, Dickinson wins FDA nod for flu, COVID, RSV combo test
Feb 08Becton, Dickinson Q1 2023 Earnings Preview
Feb 01Becton, Dickinson declares $0.91 dividend
Jan 24We Think Becton Dickinson (NYSE:BDX) Can Stay On Top Of Its Debt
Jan 09CerTest/Becton, Dickinson's test for monkeypox gets FDA emergency use nod
Jan 09Becton, Dickinson: A Quality Defensive Pick For 2023
Dec 20Estimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)
Dec 01Becton Dickinson (NYSE:BDX) Is Increasing Its Dividend To $0.91
Nov 13Becton, Dickinson Q4 2022 Earnings Preview
Nov 09Becton, Dickinson, Biocorp team up for traceability of injectable drugs
Oct 18Becton, Dickinson: Buy In Now While You Can
Oct 12Does Becton Dickinson (NYSE:BDX) Have A Healthy Balance Sheet?
Oct 05BD, Certest Biotec launch monkeypox test
Sep 26Revenue & Expenses BreakdownBeta
Revenue & Expenses Breakdown
BetaHow Becton Dickinson makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 19,492 | 1,265 | 4,843 | 1,214 |
| 30 Sep 23 | 19,372 | 1,470 | 4,817 | 1,237 |
| 30 Jun 23 | 19,046 | 1,582 | 4,848 | 1,256 |
| 31 Mar 23 | 18,809 | 1,556 | 4,791 | 1,266 |
| 31 Dec 22 | 18,738 | 1,486 | 4,751 | 1,255 |
| 30 Sep 22 | 18,870 | 1,545 | 4,726 | 1,256 |
| 30 Jun 22 | 18,958 | 1,412 | 4,774 | 1,324 |
| 31 Mar 22 | 18,924 | 1,430 | 4,845 | 1,339 |
| 31 Dec 21 | 18,534 | 1,079 | 4,750 | 1,302 |
| 30 Sep 21 | 19,131 | 1,514 | 4,720 | 1,279 |
| 30 Jun 21 | 19,066 | 1,486 | 4,632 | 1,210 |
| 31 Mar 21 | 18,313 | 1,379 | 4,409 | 1,142 |
| 31 Dec 20 | 18,207 | 1,507 | 4,346 | 1,117 |
| 30 Sep 20 | 16,074 | 245 | 4,178 | 1,039 |
| 30 Jun 20 | 16,917 | 786 | 4,216 | 1,067 |
| 31 Mar 20 | 17,414 | 923 | 4,313 | 1,057 |
| 31 Dec 19 | 17,355 | 760 | 4,379 | 1,044 |
| 30 Sep 19 | 17,290 | 1,081 | 4,334 | 1,032 |
| 30 Jun 19 | 17,108 | 784 | 4,345 | 1,039 |
| 31 Mar 19 | 17,036 | 926 | 4,353 | 1,063 |
| 31 Dec 18 | 17,063 | 894 | 4,325 | 1,071 |
| 30 Sep 18 | 15,983 | 159 | 4,029 | 1,004 |
| 30 Jun 18 | 14,747 | 621 | 3,689 | 947 |
| 31 Mar 18 | 13,503 | -99 | 3,325 | 857 |
| 31 Dec 17 | 12,251 | 294 | 2,991 | 783 |
| 30 Sep 17 | 12,093 | 1,030 | 2,953 | 770 |
| 30 Jun 17 | 12,158 | 759 | 2,947 | 807 |
| 31 Mar 17 | 12,321 | 1,314 | 2,957 | 827 |
| 31 Dec 16 | 12,419 | 1,309 | 2,966 | 823 |
| 30 Sep 16 | 12,483 | 976 | 3,005 | 828 |
| 30 Jun 16 | 12,312 | 1,139 | 2,966 | 771 |
| 31 Mar 16 | 12,234 | 810 | 2,988 | 743 |
| 31 Dec 15 | 11,217 | 688 | 2,767 | 690 |
| 30 Sep 15 | 10,282 | 695 | 2,563 | 632 |
| 30 Jun 15 | 9,410 | 815 | 2,350 | 570 |
| 31 Mar 15 | 8,448 | 1,079 | 2,127 | 529 |
| 31 Dec 14 | 8,468 | 1,150 | 2,141 | 527 |
| 30 Sep 14 | 8,446 | 1,185 | 2,145 | 524 |
| 30 Jun 14 | 8,345 | 974 | 2,117 | 522 |
| 31 Mar 14 | 8,239 | 941 | 2,102 | 506 |
| 31 Dec 13 | 8,169 | 930 | 2,091 | 502 |
| 30 Sep 13 | 8,054 | 929 | 2,059 | 494 |
| 30 Jun 13 | 7,920 | 1,114 | 2,004 | 490 |
Quality Earnings: BDX has a large one-off loss of $709.0M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: BDX's current net profit margins (6.5%) are lower than last year (7.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BDX's earnings have grown by 13.5% per year over the past 5 years.
Accelerating Growth: BDX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: BDX had negative earnings growth (-14.9%) over the past year, making it difficult to compare to the Medical Equipment industry average (3.3%).
Return on Equity
High ROE: BDX's Return on Equity (5.1%) is considered low.